Evidence map›Paper›PMID 39351692›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2024

A systematic PCR record-based re-call of HCV-RNA-positive people enables re-linkage to care and HCV elimination in Austria - The ELIMINATE project.

Lorenz Balcar, Michael Schwarz, Livia Dorn, Mathias Jachs, Lukas Hartl, Lukas Weseslindtner, Nikolaus Pfisterer, Barbara Hennlich, Annika Stückler, Robert Strassl and 27 more

Abstract readMulticenter Study
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A systematic PCR record-based re-call of HCV-RNA-positive people enables re-linkage to care and HCV elimination in Austria - The ELIMINATE project.Liver international : official journal of the International Association for the Study of the Liver · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Lorenz BalcarDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6708-3061
Michael SchwarzDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-2587-1385
Livia DornInternal Medicine II, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria.
Mathias JachsDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2871-4147
Lukas HartlDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3398-6120
Lukas WeseslindtnerCenter for Virology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-8950-937X
Nikolaus PfistererDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-1336-7250
Barbara HennlichDepartment of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.
Annika StücklerDepartment of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.
Robert StrasslClinical Institute for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-2157-0382
Astrid Voill-GlaningerCentral Laboratory and Blood Bank, Klinik Landstraße, Vienna, Austria.
Wolfgang HüblCentral Laboratory, Klinik Ottakring, Vienna, Austria.
Martin WillheimClinical Institute of Laboratory Medicine, University Clinic St. Pölten, St. Pölten, Austria.
Karin KöhrerInstitute of Medical-Chemical and Molecular biological Laboratory Diagnostics with Blood Depot, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.
Sonja Jansen-SkoupyInstitute of Laboratory Diagnostics, Klinik Favoriten, Vienna, Austria.
Sabine TomezInstitute of Laboratory Medicine with Blood Depot, Klinik Donaustadt, Vienna, Austria.
Walter KruglugerInstitute of Laboratory Medicine with Blood Depot, Klinik Donaustadt, Vienna, Austria.
Christian MadlDepartment of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.
Lukas BurghartDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9867-9829
Lukas AntonitschDepartment of Internal Medicine, Gastroenterology and Hepatology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.
Gerhard WeidingerDepartment of Internal Medicine, Gastroenterology and Hepatology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.
Florian RiedlInternal Medicine II, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria.
Hermann LaferlDepartment of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.
Julian HindDepartment of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.
Christoph WenischDepartment of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.
Christian SebestaDepartment of Internal Medicine and Gastroenterology, Klinik Floridsdorf, Vienna, Austria.
Julia Wachter-WelzlDepartment of Internal Medicine II, Landesklinikum Mistelbach, Mistelbach, Austria.
Paul WatzlDepartment of Internal Medicine II, Barmherzige Schwestern Hospital, Vienna, Austria.
Magdalena NeuhauserDepartment of Internal Medicine II, Barmherzige Schwestern Hospital, Vienna, Austria.
David ChromyDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-1807-8258
Mattias MandorferDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2330-0017
Daniela SchmidAustrian Agency for Health and Food Safety (AGES), Vienna, Austria.
Michael GschwantlerDepartment of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.
Thomas ReibergerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4590-3583
Andreas MaieronInternal Medicine II, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria.ORCID 0000-0003-4525-3549
David J M BauerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9363-8518
Caroline SchwarzDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-7762-7483

Funding

Gilead Sciences
6 · The paper itself

Abstract

BACKGROUND AND

aimsIdentification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal. Therefore, the ELIMINATE(ELIMINation of HCV in AusTria East) project aimed to systematically re-link people with a 'last-positive' HCV-RNA PCR record to care.

methodsIn 10 major liver centres in Eastern Austria, a systematic readout of 'last-positive' HCV-RNA PCR test records obtained between 2008 and 2020 were conducted and linked to available patient contact data. Between 2020 and 2023, individuals were contacted first by phone, then by letter, to inform them about the availability of effective direct-acting antiviral (DAA) treatment and invite them for pre-treatment evaluation.

resultsThe overall cohort of last-positive HCV+ individuals included 5695 subjects (62.5% males, mean age 57.3 ± 17.3 years); of note, 1931 (34%) of them had died and 759 (13%) individuals had no valid contact information. Of the remaining 3005 individuals, 1171 (40.0%) had already achieved sustained virological response (SVR) at the time of re-call. We successfully reached 617 (20.5%), of whom 417 (67.6%) attended their pre-treatment visit, and 397 (64.3%) commenced DAA-therapy. HCV cure has been confirmed in 326 individuals, corresponding to an SVR rate of 82.1%.

conclusionThe ELIMINATE project identified 5695 people living with HCV who were 'lost to care' despite documented HCV viraemia. While invalid contact data were an evident barrier to HCV elimination, premature deaths among the cohort underscored the severity of untreated HCV. The implementation of a systematic HCV-RNA PCR recorded-based re-call workflow represents an effective strategy supporting the WHO goal of HCV elimination.

Indexed as

Antiviral AgentsHepacivirusRNA, ViralAdultAgedAustriaDisease EradicationFemaleHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedPolymerase Chain ReactionSustained Virologic ResponseAntiviral AgentsRNA, ViralDAAeliminationhepatitis CWHO

Identifiers

PMID39351692
PMCPMC11586887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.